Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chengdu Pukang Weixin Biotechnology

Request full access

Specializing in polypeptide drug side chains and PEG derivatives

ChinaFounded 2018

About Chengdu Pukang Weixin Biotechnology

Chengdu Pukang Weixin Biotechnology Co., Ltd., also referred to as Pukang Bio, is a biopharmaceutical manufacturer established in 2008. The company specializes in the research, development, production, and sale of polypeptide long-acting drug side chains and single-molecule polyethylene glycol (PEG) derivatives. Pukang Bio operates as a Contract Development and Manufacturing Organization (CDMO), providing services to healthcare and pharmaceutical companies worldwide, with sales markets in East Asia, Europe, North America, and South Asia.

The company has developed a polypeptide long-acting modifier platform that supplies various peptide side chain molecules and offers design, research, and documentation services. These products, including aliphatic alkane, MIPA, and cholesterol series, are utilized in drugs for conditions like GLP-1 and HIV to extend their half-life and improve patient compliance. Pukang Bio has also built an extensive library of small-molecule PEG derivative blocks, which are used in biomedical applications such as drug delivery, ADC conjugation, and to enhance the stability of nucleic acid drugs like siRNA. Its product portfolio includes advanced intermediates, excipients, LINKERs, and various amino acids and their derivatives.

Pukang Bio is a privately held, venture capital-backed company. It has secured multiple funding rounds, including a Series B in October 2023 and a Series B1 in June 2024, with investors such as IDG Capital, GL Ventures, and Mirae Asset Global Investments. To support its operations, the company has a 3,000-square-meter R&D center, a pilot-scale laboratory, and a 60,000-square-meter production base that complies with GMP standards.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
13.7/100
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jun 2024 $28M $110M IDG Capital · Hillhouse Capital · Mirae Asset Venture Investment · Huimei Technology ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Chengdu Pukang Weixin Biotechnology website traffic

Latest recorded traffic for Chengdu Pukang Weixin Biotechnology is 410 monthly website visits.

Latest monthly visits410
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chengdu Pukang Weixin Biotechnology in its local ecosystem

Live from Dealroom

The Chengdu Pukang Weixin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chengdu Pukang Weixin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Pukang Weixin Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.